Key Highlights
- Third-quarter Revenue rose 49% to USD 10.2 million from USD 6.8 million, with core revenue up 27% to USD 8.2 million and program-related milestone and Royalty revenue of USD 2.0 million against USD 0.4 million.
- Management raised standalone 2026 revenue guidance to at least USD 34.5 million, up from about USD 34 million in October and an earlier range of USD 30 million to USD 32 million.
- On November 9, 2026 the company agreed to acquire Akron Bio for about USD 151.8 million, made up of USD 105 million in cash, shares valued at about USD 26.8 million and USD 20 million of deferred payments.
- Cash, equivalents and investments were USD 132.7 million with no Debt at September 30, 2026, and management expects USD 40 million to USD 45 million of cash after the deal closes.
Instrument Pull-Forward and Royalties Lift Third-Quarter Sales
MaxCyte (NASDAQ:MXCT) filed its Quarterly Report on November 10, 2026 and held its Earnings Call the same day. The company sells electroporation instruments, disposable assemblies and licenses that help cell therapy developers engineer cells. Instrument revenue doubled to USD 2.8 million from USD 1.4 million, helped by a partner pulling forward purchases first expected in the fourth quarter. Processing assembly revenue was USD 3.1 million against USD 2.6 million, and license revenue was USD 2.0 million against USD 1.8 million. Operating expenses fell to USD 14.5 million from USD 19.4 million, and the nine-month net loss was USD 18.4 million on USD 27.1 million of revenue.
How the USD 151.8 Million Akron Bio Purchase Is Structured
Akron Bio supplies GMP-grade reagents and materials used before and after electroporation, and is being bought from affiliates of Arcline Investment Management. Besides the USD 105 million of cash, the company will issue 20,639,733 shares and owe USD 10 million each in January 2028 and January 2029. To protect Liquidity it also arranged a Credit Facility of up to USD 75 million, with a USD 20 million term Loan draw and a USD 2 million revolver draw expected at closing. On the call, management said Akron should generate about USD 28 million of 2026 revenue, about USD 7 million to USD 8 million of EBITDA and a gross Margin in the mid-60% range. Closing is expected before the end of 2026.
Guidance, Cash Burn and Integration Risks After the Deal
The raised 2026 outlook is for MaxCyte standalone and excludes Akron. It splits into about USD 28 million of core revenue and at least USD 6.5 million of milestones and royalties, and management expects standalone cash burn of about USD 17 million this year. For the combined company, management said it expects annual cash burn below USD 10 million in 2027. The filing says the deal may not close on time or at all, and would add interest expense and amortization. Issuing shares also dilutes existing holders, and cash would fall sharply from USD 132.7 million.
Where Things Stand
Mostly with cash on hand, plus new shares, deferred payments and debt, so execution matters. MaxCyte (NASDAQ:MXCT) has a debt-free Balance Sheet and rising revenue, but the Akron Bio purchase would use most of its cash, add a credit facility and dilute shareholders by 20.6 million new shares. Management said the acquired Business is profitable and combined burn falls below USD 10 million in 2027. Next markers are the expected closing before the end of 2026, fourth-quarter royalty and instrument trends, and first combined results.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...